Bid Cleavage and TRAIL Sensitivity in Urothelial Cell Carcinoma of the Bladder

doi:10.13188/2380-0585.1000022

Abstract

Highlights

The American Cancer Society’s estimated that 81,190 new cases will be diagnosed with bladder cancer in 2018 [1]
The majority of urothelial cell carcinoma of the bladder (UCCB) are amenable to intravesical bacillus calmette-guérin (BCG) immunotherapy after initial tumor resection, which is considered the treatment of choice to date [3]
Using our in-vitro multicellular spheroids (MCS) model, we found that topical application of tumor necrosis factor related apoptosisinducing ligand (TRAIL) resulted in selective killing of peripheral MGH-U3 (UCC) cells with sparing of the central normal fibroblast cells (Figure 1)

Summary

Introduction

The American Cancer Society’s estimated that 81,190 new cases will be diagnosed with bladder cancer in 2018 [1]. About 80% of bladder cancers present as non-invasive urothelial cell carcinoma of the bladder (UCCB) [2]. The understanding of apoptosis has provided the basis for novel targeted therapies that can induce death in cancer cells or sensitize them to other established cytotoxic agents and radiation therapy. One such agent is tumor necrosis factor related apoptosisinducing ligand (TRAIL), a unique member of the tumor necrosis factor (TNF) superfamily, which can selectively trigger apoptosis in a broad range of cancer cells while sparing normal cells [5]. It has been shown that decreasing the degree of TRAIL crosslinking and

Methods

Results

Conclusion